February 25, 2024
Recombinant Therapeutic Antibodies and Proteins Market

Recombinant Therapeutic Antibodies and Proteins Market Propelled by growing demand for next generation biologics.

Recombinant therapeutic antibodies and proteins are purified biological molecules produced through recombinant DNA technology, offering significant advantages over conventional drug molecules. Recombinant therapeutic antibodies and proteins have emerged as an important class of biologic drugs for the treatment of various chronic and life-threatening conditions such as cancer, autoimmune disorders, infectious diseases, and other disorders. The demand for recombinant therapeutics antibodies and proteins has witnessed a strong surge in recent years owing to growing need for precise and selective treatment approaches.

The global Recombinant Therapeutic Antibodies and Proteins Market is estimated to be valued at US$ 125.5 billion  in 2023 and is expected to exhibit a CAGR of 8.5% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Growing demand for next generation biologics is one of the major trends propelling the growth of the global recombinant therapeutic antibodies and proteins market. Next generation biologics such as bispecific antibodies are emerging as a promising class of drugs offering enhanced efficacy and safety. Bispecific antibodies target two cells or targets simultaneously, enabling enhanced treatment selectivity. Various bispecific antibodies are in clinical development for a wide range of oncology and autoimmune conditions. For instance, Amgen’s bispecific T cell engager (BiTE) blinatumomab is approved for the treatment of B-cell precursor acute lymphoblastic leukemia. Strong pipeline of novel bispecific antibodies and expected approvals over the forecast period will augment the demand for next generation biologics thereby contributing significantly to the market growth.

SWOT Analysis
Strength: Recombinant therapeutic antibodies and proteins have demonstrated safety and efficacy in various clinical trials. They provide targeted treatment options compared to conventional drugs.

Weakness: High development costs associated with recombinant therapeutic antibodies and proteins. Require specialized storage and transport conditions.

Opportunity: Increasing incidence of chronic diseases like cancer provides growth opportunities. Expanding applications in new disease indications.

Threats: Biosimilars pose pricing pressure on patented biologics. Stringent regulatory requirements for approval.

Key Takeaways
Global Recombinant Therapeutic Antibodies And Proteins Market is expected to witness high growth.

Regional analysis comprises North America dominates the global market currently due to availability of advanced healthcare facilities and higher adoption among physicians and patients in the region. Asia Pacific is expected to witness fastest growth over the forecast period aided by expansion of biologics manufacturing capabilities in countries like China and India along with rising healthcare expenditure.

Key players operating in the recombinant therapeutic antibodies and proteins market are Eli Lilly & Company, Roche, Johnson & Johnson, Pfizer, Bayer, Amgen, Sanofi, Novartis, AbbVie, Merck & Co. These players are focusing on increasing geographic presence by establishing manufacturing and distribution agreements in high growth markets. Various collaborations between pharmaceutical companies and research institutes are also expected to aid product pipeline expansion.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it